Patents by Inventor Laurent Delpy

Laurent Delpy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365964
    Abstract: The need to identify new therapeutic approaches in the treatment of cancers of the B lymphoid lineage is crucial. Here, the inventors provide evidence for efficient knockdown of c-REL and RELA expression after treatment with splice switching antisense oligonucleotides (SSO) inducing exon skipping and reading frameshift. For instance, treatments with morpholino SSO targeting c-REL exon 2 donor splice site or RELA exon 5 acceptor splice site elicited very efficient knockdown in diffuse large B cell lymphoma (DLBCL) cell lines and antibody-secreting cells derived from primary human B cells. Consistent with the clinical relevance of c-REL activation in DLBCL, treatment with c-REL SSO induced major alterations in NF-?B and TNF signalling pathways and strongly decreased cell viability. Altogether, SSO-mediated knockdown is a powerful approach to inhibit transiently the expression of a NF-?B component in B-lineage cells that should open new avenues for cancer treatments.
    Type: Application
    Filed: September 9, 2021
    Publication date: November 16, 2023
    Inventors: Laurent DELPY, Anne MARCHALOT, Jean FEUILLARD, Francois BOYER, Nathalie FAUMONT
  • Publication number: 20220235360
    Abstract: Immunoglobulins (Ig) are expressed either on the surface of B cells or as secreted antibodies by plasma cells that represents the final stage of B cell differentiation. The present invention involves the use of antisense oligonucleotides (ASOs) for either reducing the production of the secreted form or either reducing the production of the membrane form. In particular, the inventors show that antisense oligonucleotides masking the secretory polyadenylation signal induce a decrease in the production of the secreted immunoglobulin. Inversely, antisense oligonucleotides masking the membrane polyadenylation signal induce a decrease in the production of the membrane-anchored immunoglobulin. The proof of concept has been obtained using an ASO hybridizing to the polyadenylation signal (PAS) sequence of the transcript encoding the secreted form of IgE. Indeed, the targeting of this PAS sequence induces a drastic decrease in IgE production.
    Type: Application
    Filed: June 3, 2020
    Publication date: July 28, 2022
    Inventors: Laurent DELPY, Michel COGNÉ, Brice LAFFLEUR, Anne MARCHALOT
  • Patent number: 10398722
    Abstract: The present invention concerns a treatment of diseases involving B cells, B lymphocytes or plasmocytes. In particular, it concerns an antisense oligonucleotide or a mixture of antisense oligonucleotides capable of inducing exon skipping at the RNA of the immunoglobulin heavy or light chains, for the use of same in the treatment of diseases involving B cells.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 3, 2019
    Assignees: Universite de Limoges, Centre National de la Recherche Scientifique
    Inventors: Laurent Delpy, Nivine Srour, Michel Cogné
  • Publication number: 20180344760
    Abstract: The present invention concerns a treatment of diseases involving B cells, B lymphocytes or plasmocytes. In particular, it concerns an antisense oligonucleotide or a mixture of antisense oligonucleotides capable of inducing exon skipping at the RNA of the immunoglobulin heavy or light chains, for the use of same in the treatment of diseases involving B cells.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 6, 2018
    Applicants: Universite de Limoges, Centre National de la Recherche Scientifique
    Inventors: Laurent Delpy, Nivine Srour, Michel Cogné